Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Supaglutide in Type 2 Diabetes Suboptimally Controlled on Diet and Exercise
NCT04994288Phase 3Completed
- Sponsor
- Shanghai Innogen Pharmaceutical Technology Co., Ltd.
- Start
- Aug 2021
- Primary completion
- Jun 2023
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of efsubaglutide alfa in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Shanghai Innogen Pharmaceutical Technology Co., Ltd. Primary endpoint: Glycated Hemoglobin at 52 weeks. Started Aug 2021; status: completed.
02
Drugs
efsubaglutide alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04994288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994288.